127 related articles for article (PubMed ID: 21946310)
1. Unilateral nigrostriatal 6-hydroxydopamine lesions in mice II: predicting l-DOPA-induced dyskinesia.
Smith GA; Heuer A; Dunnett SB; Lane EL
Behav Brain Res; 2012 Jan; 226(1):281-92. PubMed ID: 21946310
[TBL] [Abstract][Full Text] [Related]
2. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
[TBL] [Abstract][Full Text] [Related]
3. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
Winkler C; Kirik D; Björklund A; Cenci MA
Neurobiol Dis; 2002 Jul; 10(2):165-86. PubMed ID: 12127155
[TBL] [Abstract][Full Text] [Related]
4. L-DOPA-elicited abnormal involuntary movements in the rats damaged severely in substantia nigra by 6-hydroxydopamine.
Wang R; Shao M
Ann Palliat Med; 2020 May; 9(3):947-956. PubMed ID: 32279520
[TBL] [Abstract][Full Text] [Related]
5. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.
Lundblad M; Picconi B; Lindgren H; Cenci MA
Neurobiol Dis; 2004 Jun; 16(1):110-23. PubMed ID: 15207268
[TBL] [Abstract][Full Text] [Related]
6. Counteraction by nitric oxide synthase inhibitor of neurochemical alterations of dopaminergic system in 6-OHDA-lesioned rats under L-DOPA treatment.
Del-Bel E; Padovan-Neto FE; Szawka RE; da-Silva CA; Raisman-Vozari R; Anselmo-Franci J; Romano-Dutra AC; Guimaraes FS
Neurotox Res; 2014 Jan; 25(1):33-44. PubMed ID: 23807548
[TBL] [Abstract][Full Text] [Related]
7. Dramatic differences in susceptibility to l-DOPA-induced dyskinesia between mice that are aged before or after a nigrostriatal dopamine lesion.
Bez F; Francardo V; Cenci MA
Neurobiol Dis; 2016 Oct; 94():213-25. PubMed ID: 27312773
[TBL] [Abstract][Full Text] [Related]
8. Effects of amphetamine and 6-hydroxydopamine lesions on reserpine-induced oral dyskinesia.
Neisewander JL; Castañeda E; Davis DA; Elson HJ; Sussman AN
Eur J Pharmacol; 1996 Jun; 305(1-3):13-21. PubMed ID: 8813526
[TBL] [Abstract][Full Text] [Related]
9. Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia.
Mantas I; Yang Y; Mannoury-la-Cour C; Millan MJ; Zhang X; Svenningsson P
Neuropharmacology; 2020 Jan; 162():107829. PubMed ID: 31666199
[TBL] [Abstract][Full Text] [Related]
10. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
[TBL] [Abstract][Full Text] [Related]
11. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Shin E; Rogers JT; Devoto P; Björklund A; Carta M
Exp Neurol; 2014 Jul; 257():25-38. PubMed ID: 24747357
[TBL] [Abstract][Full Text] [Related]
12. Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice.
Ruiz-DeDiego I; Mellstrom B; Vallejo M; Naranjo JR; Moratalla R
Biol Psychiatry; 2015 Jan; 77(2):95-105. PubMed ID: 24857398
[TBL] [Abstract][Full Text] [Related]
13. 3-O-methyl-DOPA is not involved in the development of behavioral supersensitivity after repeated L-dopa administration in 6-OHDA lesioned rats.
Bräutigam K; Sohr R; Morgenstern R
Behav Brain Res; 1994 Jul; 63(1):41-5. PubMed ID: 7945976
[TBL] [Abstract][Full Text] [Related]
14. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
[TBL] [Abstract][Full Text] [Related]
15. Anti-dyskinetic effect of the neuronal nitric oxide synthase inhibitor is linked to decrease of FosB/deltaFosB expression.
Padovan-Neto FE; Ferreira NR; de Oliveira-Tavares D; de Aguiar D; da Silva CA; Raisman-Vozari R; Del Bel E
Neurosci Lett; 2013 Apr; 541():126-31. PubMed ID: 23428503
[TBL] [Abstract][Full Text] [Related]
16. Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I: motor impairments identify extent of dopamine depletion at three different lesion sites.
Heuer A; Smith GA; Lelos MJ; Lane EL; Dunnett SB
Behav Brain Res; 2012 Mar; 228(1):30-43. PubMed ID: 22146593
[TBL] [Abstract][Full Text] [Related]
17. The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
Thornton E; Hassall MM; Corrigan F; Vink R
Parkinsonism Relat Disord; 2014 May; 20(5):508-13. PubMed ID: 24637127
[TBL] [Abstract][Full Text] [Related]
18. Drug-induced rotation intensity in unilateral dopamine-depleted rats is not correlated with end point or qualitative measures of forelimb or hindlimb motor performance.
Metz GA; Whishaw IQ
Neuroscience; 2002; 111(2):325-36. PubMed ID: 11983318
[TBL] [Abstract][Full Text] [Related]
19. Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra.
Konieczny J; Czarnecka A; Lenda T; Kamińska K; Lorenc-Koci E
Behav Brain Res; 2014 Mar; 261():79-88. PubMed ID: 24361083
[TBL] [Abstract][Full Text] [Related]
20. Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.
Barnum CJ; Eskow KL; Dupre K; Blandino P; Deak T; Bishop C
Neuroscience; 2008 Sep; 156(1):30-41. PubMed ID: 18687386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
